COMPLEXIN-1 Protein

COMPLEXIN-1 Protein (CPLX1)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="text-align:center;">COMPLEXIN-1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Complexin-1</td></tr>
<tr><td><strong>Encoded by</strong></td><td>[CPLX1](/genes/cplx1)</td></tr>
<tr><td><strong>UniProt</strong></td><td>[O75178](https://www.uniprot.org/uniprotkb/O75178/entry)</td></tr>
<tr><td><strong>Localization</strong></td><td>Presynaptic cytosol, synaptic vesicles</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Synaptic vesicle fusion regulator</td></tr>
<tr><td><strong>Major Pathway</strong></td><td>[Synaptic Transmission](/mechanisms/synaptic-transmission)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

COMPLEXIN-1 (CPLX1) is a 134-amino acid presynaptic cytosolic protein that plays a critical role in regulating synaptic vesicle fusion. It binds to assembled SNARE complexes and controls the final step of calcium-triggered synaptic vesicle fusion, acting as both a fusion clamp and a fusion facilitator[@reim2005][@xue2007]. This dual function makes complexin-1 essential for precise temporal control of neurotransmitter release.

COMPLEXIN-1 Protein (CPLX1)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="text-align:center;">COMPLEXIN-1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Complexin-1</td></tr>
<tr><td><strong>Encoded by</strong></td><td>[CPLX1](/genes/cplx1)</td></tr>
<tr><td><strong>UniProt</strong></td><td>[O75178](https://www.uniprot.org/uniprotkb/O75178/entry)</td></tr>
<tr><td><strong>Localization</strong></td><td>Presynaptic cytosol, synaptic vesicles</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Synaptic vesicle fusion regulator</td></tr>
<tr><td><strong>Major Pathway</strong></td><td>[Synaptic Transmission](/mechanisms/synaptic-transmission)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

COMPLEXIN-1 (CPLX1) is a 134-amino acid presynaptic cytosolic protein that plays a critical role in regulating synaptic vesicle fusion. It binds to assembled SNARE complexes and controls the final step of calcium-triggered synaptic vesicle fusion, acting as both a fusion clamp and a fusion facilitator[@reim2005][@xue2007]. This dual function makes complexin-1 essential for precise temporal control of neurotransmitter release.

In the nervous system, complexin-1 is expressed in most neuronal populations, with particularly high expression in cerebellar neurons, hippocampal pyramidal cells, and dopaminergic neurons. Its function is essential for normal synaptic transmission, and alterations in complexin-1 biology have been linked to disrupted neurotransmission in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[@selkoe2002][@bridi2018][@fogarty2019].

Because synaptic failure is an early and convergent event across neurodegenerative diseases, CPLX1 is relevant beyond pure synaptic physiology. The protein serves as a mechanistic marker and experimental target for understanding synaptic dysfunction in disease states.

Domain Architecture and Molecular Function

Primary Structure

Complexin-1 is a small protein (~15 kDa) with four functionally distinct regions[@xue2007][@rizo2008]:

• N-terminal Activating Segment (1-50 aa): This region supports efficient calcium-triggered release. It contains the "激活" (activation) function that promotes fusion when calcium enters the presynaptic terminal.
• Accessory Helix (50-75 aa): This α-helix contributes to clamping of premature fusion by competing with synaptotagmin for SNARE complex binding.
• Central Helix (75-110 aa): The central region contains the high-affinity SNARE-binding helix that binds to assembled SNARE bundles.
• C-terminal Segment (110-134 aa): This region supports membrane association and spatial positioning at the active zone.

Structure-Function Relationships

The domain architecture enables rapid switching between fusion states:

Normal Cellular Functions

Release Synchronization

At fast synapses, complexin-1 tightens temporal precision of vesicle fusion[@reim2005][@rizo2008]:

• Reduces jitter in neurotransmitter release
• Preserves signal-to-noise during high-frequency activity
• Enables millisecond-precision timing required for neural coding

Spontaneous Release Suppression

Loss of complexin function generally elevates spontaneous fusion while impairing evoked synchronous release[@xue2007][@kaeserwoo2012]:

• The clamping function prevents premature fusion
• Activation function enables fast synchronized release
• These functions are coupled, not separate

Circuit-Level Outcomes

CPLX1-dependent release control is especially relevant in:

• Cerebellar Circuits: Purkinje cell synapse timing
• Hipppocampal Circuits: Memory and learning
• Basal Ganglia Circuits: Movement control
• Motor Endplates: Neuromuscular junction function

Role in Neurodegenerative Diseases

Alzheimer Disease

Synaptic decline in AD includes altered levels of presynaptic proteins involved in vesicle priming and fusion[@selkoe2002][@de2016]:

• Altered Expression: Complexin-1 levels change in AD brain tissue
• Synaptic Homeostasis Failure: Changes are interpreted as indicators of failing release homeostasis
• Hippocampal Vulnerability: CA1 and entorhinal cortex synapses are particularly affected
• Early Marker: Synaptic changes may precede clinical symptoms

Parkinson Disease

In PD, presynaptic stress, dopamine-terminal degeneration, and alpha-synuclein toxicity converge on release machinery[@bridi2018][@fogarty2019]:

• Alpha-Synuclein Toxicity: α-Synuclein aggregation impairs vesicle release machinery
• Dopaminergic Vulnerability: Complexin-1 is functionally impaired in substantia nigra neurons
• Presynaptic Stress: Dopaminergic terminals are particularly vulnerable to oxidative stress
• Release Dysregulation: Impaired complexin function contributes to neurotransmission deficits

Amyotrophic Lateral SALS

In ALS, cortical and spinal synaptic dysfunction precedes extensive neuronal death[@fogarty2019][@sleigh2014][@kim2019]:

• Motor Network Instability: CPLX1-related release dysregulation impairs adaptive plasticity
• Corticospinal Vulnerability: Upper motor neuron synapses are affected early
• Neuromuscular Junction: Distal axon terminals degenerate before cell bodies
• Synaptic Proteins: Altered expression of complexin and other SNARE regulators

Other Neurodegenerative Conditions

Complexin-1 dysfunction has been implicated in:

• Huntington's Disease: Altered release at striatal synapses
• Down Syndrome: Synaptic protein changes similar to AD
• Schizophrenia: Altered prefrontal cortical synapses

Molecular Mechanisms in Disease

SNARE Complex Dysregulation

Complexin-1 regulates SNARE complex function:

Disease states alter this regulation:

• Altered Expression: Changes in complexin levels disrupt the balance
• Post-Translational Modifications: Phosphorylation affects function
• Protein Aggregation: α-Synuclein may sequester complexin

Synaptic Vesicle Cycling

The synaptic vesicle cycle is disrupted in neurodegeneration[@martin2020]:

• Vesicle Pool Depletion: Impaired replenishment of release-ready vesicles
• Endocytosis Defects: Slow vesicle recycling
• Priming Abnormalities: Reduced readily-releasable pool size

Therapeutic Approaches

Current Strategies

Gene Therapy Approaches

• CPLX1 Overexpression: Deliver additional complexin-1
• AAV-Mediated Delivery: Target specific brain regions
• Combination Therapies: With other synaptic proteins

Research Directions

• Biomarker Development: Complexin levels as disease markers
• iPSC Models: Patient-derived neurons for drug screening
• Small Molecule Screens: Identify fusion modulators

Interactions with Other Proteins

Complexin-1 interacts with key synaptic proteins:

| Protein | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| SNAP-25 | Direct binding | SNARE complex formation |
| Syntaxin-1A | Direct binding | SNARE complex formation |
| VAMP2 | Direct binding | Synaptic vesicle SNARE |
| Synaptotagmin-1 | Competitive binding | Calcium sensing |
| Munc13 | Indirect | Vesicle priming |
| Munc18 | Indirect | Syntaxin regulation |

Neuropathology

Brain Regions Affected

• Hippocampus: CA1 pyramidal cells, entorhinal cortex
• Cerebellum: Purkinje cells, granule cells
• Substantia Nigra: Dopaminergic neurons
• Motor Cortex: Upper motor neurons
• Spinal Cord: Anterior horn cells, motor neurons

Pathological Features

• Synaptic Loss: Reduced synapse numbers
• Vesicle Abnormalities: Altered vesicle pool morphology
• SNARE Changes: Altered SNARE protein levels
• Active Zone Defects: Reduced active zone complexity

Research Background

Key milestones in complexin research:

• 1995: Discovery of complexin function in neurotransmitter secretion
• 2005: Crystal structure and mechanism clarification
• 2007: Domain mapping reveals dual function
• 2012: C-terminal clamp function elucidated
• 2017-2021: Links to neurodegenerative disease established

See Also

• [CPLX1 Gene](/genes/cplx1)
• [COMPLEXIN-2 Protein](/proteins/complexin-2-protein)
• [SNARE Complex](/proteins/snare-complex)
• [Synaptotagmin-1 Protein](/proteins/synaptotagmin-1-protein)
• [Syntaxin-1A Protein](/proteins/syntaxin-1a-protein)
• [SNAP-25 Protein](/proteins/snap25-protein)
• [Synaptic Dysfunction in Neurodegenerative Diseases](/mechanisms/synaptic-dysfunction)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [UniProt: CPLX1](https://www.uniprot.org/uniprotkb/O75178/entry)
• [NCBI Gene: CPLX1](https://www.ncbi.nlm.nih.gov/gene/10815)
• [Allen Brain Atlas](https://brain-map.org/)
• [Synaptic Protein Database](https://synapticproteome.ucla.edu/)

References